Form 4: Bristol-Myers Squibb Executive Adam Lenkowsky Reports Changes in Beneficial Ownership
SEC Form 4
EVP, Chief Commercial Officer of Bristol-Myers Squibb, Adam Lenkowsky, reports transactions involving common stock and market share/performance units, including vesting, adjustments, and tax withholdings.
Summary
- Adam Lenkowsky, EVP, Chief Commercial Officer of Bristol-Myers Squibb, filed a Form 4 detailing changes in his beneficial ownership of company stock and derivative securities.
- The transactions occurred on March 10, 2024, and involve common stock, market share units, and performance shares.
- These transactions include the vesting of market share units granted in 2020 and 2021, as well as the distribution of performance shares earned under the 2021-2023 Long-Term Performance Award.
- Adjustments were made to the number of shares acquired upon vesting of market share units due to performance factors.
- Shares were withheld for payment of taxes upon vesting of awards.
- Some market share units granted in 2022 and 2023 were cancelled because the minimum payout factor was not achieved.
- Lenkowsky also acquired additional market share units and performance shares that will vest in future years.
- The report also reflects holdings in the BMS Savings and Investment Program and by spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document primarily reports transactions related to executive compensation. While some market share units were cancelled due to not meeting performance targets, other awards vested and were distributed, suggesting mixed performance.
Positives
- The vesting of market share units and distribution of performance shares indicate that certain performance targets were met, at least for the 2020, 2021 and 2021-2023 periods.
- The executive's continued holding of a significant number of shares and derivative securities suggests confidence in the company's future performance.
Negatives
- The cancellation of market share units granted in 2022 and 2023 due to not achieving the minimum payout factor suggests that performance targets were not met for those periods.
- Shares were withheld for payment of taxes upon vesting of awards, which reduces the number of shares beneficially owned.
Risks
- The value of market share units is dependent on the company's stock price performance, which can be volatile.
- Future performance share payouts are subject to the achievement of Total Shareholder Return (TSR) targets, which may not be met.
- Changes in company strategy or market conditions could impact the value of the executive's holdings.
Future Outlook
The document indicates future vesting dates for market share units and distribution dates for performance shares, contingent on continued employment and achievement of performance targets.
Industry Context
Executive compensation and stock ownership are common practices in the pharmaceutical industry to align management's interests with those of shareholders. Form 4 filings provide transparency into these transactions.
Comparison to Industry Standards
- Stock options, restricted stock units (RSUs), and performance shares are common components of executive compensation packages in the pharmaceutical industry.
- Companies like Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ) also utilize similar equity-based compensation plans to incentivize their executives.
- The vesting schedules and performance metrics associated with these awards vary across companies, but the overall goal is to align executive pay with company performance and shareholder value creation.
- The payout factors for market share units (60%-200% or 80%-225%) are within the typical range observed in similar compensation plans.
Stakeholder Impact
- The transactions reported in this Form 4 have a limited direct impact on stakeholders.
- However, executive compensation practices can influence shareholder perceptions of corporate governance and alignment of interests.
Next Steps
- The executive will continue to hold and potentially vest in additional market share units and performance shares in future years.
- Future Form 4 filings will be required to report any further changes in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 03/10/2020 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2021 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 2021-2023 | Period for the Long-Term Performance Award, with performance shares distributed in Q1 2024. |
| 03/10/2022 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to not achieving the minimum payout factor. |
| 05/03/2023 | Date of previously filed Form 3. |
| 06/06/2023 | Date of previously filed Form 4. |
| 03/10/2023 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to not achieving the minimum payout factor. |
| 03/10/2024 | Date of transactions reported in this Form 4, including vesting of market share units and distribution of performance shares. |
| 03/12/2024 | Date of signature on the Form 4. |
| Q1 2024 | Distribution of performance shares earned under the 2021-2023 Long-Term Performance Award. |
| 03/10/2025 | Vesting date for one-quarter of market share units granted on March 10, 2021. |
| 03/10/2026 | Vesting date for one-quarter of market share units granted on March 10, 2022. |
| 03/10/2027 | Vesting date for one-quarter of market share units granted on March 10, 2023 and distribution of performance shares. |
| 03/10/2028 | Vesting date for one-quarter of market share units granted on March 10, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.